CLAIMS

1. Use of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for improving cognition in a subject suffering from Alzheimer's disease or schizophrenia, wherein said medicament is to be administered to said subject in an amount of a daily dose of from 0.1 mg-3 mg or less.

~~2. The use of claim 1 wherein the daily dose is from 0.1 mg - 3 mg.~~

~~3~~2. The use of claim 1 wherein the daily dose is from 0.3 mg - 3 mg.

~~4~~3. The use of claim 1 wherein the daily dose is from 1 mg - 3 mg.

~~5~~4. The use of claim 1 wherein the daily dose is 0.3 mg, 1 mg, 2 mg or 3 mg.

~~6~~5. The use of any of the preceding claims wherein said schizophrenia is selected from the paranoid type, disorganized type, catatonic type or the undifferentiated type.

~~7~~6. The use of any of the preceding claims wherein said salt is selected from (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate, or (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride solvate.

~~8~~7. The use of any of the preceding claims wherein said salt is (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride.

~~9~~8. The use of any of the preceding claims wherein said salt is (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate.

~~10~~9. The use of any one of the preceding claims wherein the daily dose is an oral daily dose.